keyword
https://read.qxmd.com/read/38686870/comparison-of-safety-of-acetaminophen-and-ibuprofen-in-minors-based-on-the-faers-database
#1
JOURNAL ARTICLE
Jing Wang, Guowen Feng, Dan Li, Xiaodan Zhou, Jia Chen, Fengdie Wang, Li Chen
OBJECTIVE: To investigate adverse events(ADEs) associated with the use of paracetamol and ibuprofen in people under 18 years of age. BACKGROUND: The use of NSAIDs reached a peak as a result of the spread of COVID-19 in previous years. Minors, as a special population, need to pay more attention to the use of corresponding drugs and the occurrence of adverse events (ADEs). METHODS: The population was divided into four age groups: infant group, preschool group, children group, and adolescent group...
April 30, 2024: Expert Opinion on Drug Safety
https://read.qxmd.com/read/38675472/human-abc-and-slc-transporters-the-culprit-responsible-for-unspecific-psma-617-uptake
#2
JOURNAL ARTICLE
Harun Taş, Gábor Bakos, Ulrike Bauder-Wüst, Martin Schäfer, Yvonne Remde, Mareike Roscher, Martina Benešová-Schäfer
[177 Lu]Lu-PSMA-617 has recently been successfully approved by the FDA, the MHRA, Health Canada and the EMA as Pluvicto® . However, salivary gland (SG) and kidney toxicities account for its main dose-limiting side-effects, while its corresponding uptake and retention mechanisms still remain elusive. Recently, the presence of different ATP-binding cassette (ABC) transporters, such as human breast cancer resistance proteins (BCRP), multidrug resistance proteins (MDR1), multidrug-resistance-related proteins (MRP1, MRP4) and solute cassette (SLC) transporters, such as multidrug and toxin extrusion proteins (MATE1, MATE2-K), organic anion transporters (OAT1, OAT2v1, OAT3, OAT4) and peptide transporters (PEPT2), has been verified at different abundances in human SGs and kidneys...
April 16, 2024: Pharmaceuticals
https://read.qxmd.com/read/38600804/physiologically-based-biopharmaceutics-modeling-pbbm-best-practices-for-drug-product-quality-regulatory-and-industry-perspectives-2023-workshop-summary-report
#3
REVIEW
Claire Mackie, Sumit Arora, Paul Seo, Rebecca Moody, Bhagwant Rege, Xavier Pepin, Tycho Heimbach, Christer Tannergren, Amitava Mitra, Sandra Suarez-Sharp, Luiza Novaes Borges, Shinichi Kijima, Evangelos Kotzagiorgis, Maria Malamatari, Shereeni Veerasingham, James E Polli, Gregory Rullo
Physiologically based biopharmaceutics modeling (PBBM) is used to elevate drug product quality by providing a more accurate and holistic understanding of how drugs interact with the human body. These models are based on the integration of physiological, pharmacological, and pharmaceutical data to simulate and predict drug behavior in vivo. Effective utilization of PBBM requires a consistent approach to model development, verification, validation, and application. Currently, only one country has a draft guidance document for PBBM, whereas other major regulatory authorities have had limited experience with the review of PBBM...
April 10, 2024: Molecular Pharmaceutics
https://read.qxmd.com/read/38594060/mhra-issues-further-update-on-fluoroquinolone-safety
#4
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 9, 2024: Drug and Therapeutics Bulletin
https://read.qxmd.com/read/38560357/safety-assessment-of-cenobamate-real-world-adverse-event-analysis-from-the-faers-database
#5
JOURNAL ARTICLE
Shihao Chen, Wenqiang Fang, Linqian Zhao, Huiqin Xu
OBJECTIVE: This study aims to analyze adverse drug events (ADEs) associated with cenobamate from the FAERS database, covering the third quarter of 2020 to the second quarter of 2023. METHODS: Data related to cenobamate-associated ADEs from the third quarter of 2020 to the second quarter of 2023 were collected. After standardizing the data, various signal quantification techniques, including ROR, MHRA, BCPNN, and MGPS, were employed for analysis. RESULTS: Among 2535 ADE reports where cenobamate was the primary suspected drug, 94 adverse reactions involving 11 different System Organ Class (SOC) categories were identified through the application of four signal quantification techniques...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38537425/real-world-safety-of-levetiracetam-mining-and-analysis-of-its-adverse-drug-reactions-based-on-faers-database
#6
JOURNAL ARTICLE
Zhimin He, Cuimin Liu, Lin Lin, Guowen Feng, Gang Wu
INTRODUCTION: Levetiracetam is a relatively new and widely utilized anti-seizure medication; however, limited information is available regarding its adverse effects. This study aims to thoroughly investigate, evaluate, and present evidence on the safety profile of Levetiracetam, relying on data from the FDA Adverse Event Reporting System (FAERS) database to facilitate informed clinical decision-making. METHODS: We employed various statistical measures, including Reporting Odds Ratio (ROR), Proportionate Reporting Ratio (PRR), and analysis by the Medicines and Healthcare Products Regulatory Agency (MHRA), to identify signals of adverse reactions associated with Levetiracetam...
March 21, 2024: Seizure: the Journal of the British Epilepsy Association
https://read.qxmd.com/read/38534806/the-requirements-of-managing-phase-i-clinical-trials-risks-the-british-and-italian-case-studies
#7
JOURNAL ARTICLE
Davide Di Tonno, Laura Martena, Manuela Taurisano, Caterina Perlin, Anna Chiara Loiacono, Stefano Lagravinese, Santo Marsigliante, Michele Maffia, Susanna Esposito, Gianluca Villa, Giovanni Gori, Leonardo Bray, Alessandro Distante, Alessandro Miani, Prisco Piscitelli, Alberto Argentiero
Phase I clinical trials represent a critical point in drug development because the investigational medicinal product is being tested in humans for the first time. For this reason, it is essential to evaluate and identify the Maximum Tolerated Dose (MTD) and the safety of the new compound. To mitigate the possible risks associated with drug administration and treatment, the European Competent Authority issued various guidelines to provide provisions and harmonize risk management processes. In the UK and Italy, particular attention should be paid to the Medicines & Healthcare Products Regulatory Agency (MHRA) phase I accreditation scheme and the specific rules set by the Italian Drug Authority through the AIFA Determination no...
March 13, 2024: Epidemiologia (Basel)
https://read.qxmd.com/read/38533744/collaborative-study-for-the-establishment-of-ph-eur-biological-reference-preparation-for-human-tetanus-immunoglobulin-batch-2
#8
JOURNAL ARTICLE
P Stickings, R Tierney, J Hockley, P Rigsby, E Terao
This publication describes the outcome of a project to develop a replacement European Pharmacopoeia (Ph. Eur.) Biological Reference Preparation (BRP) for Human tetanus immunoglobulin (TIg) as well as for the World Health Organization (WHO) International Standard (IS) for Tetanus Immunoglobulin, Human. Bulk TIg was kindly provided by a European manufacturer and was used to prepare the candidate standard. The candidate standard was freeze-dried and calibrated in an international collaborative study jointly co-ordinated by the Medicines & Healthcare products Regulatory Agency (MHRA) and the European Directorate for the Quality of Medicines & HealthCare (EDQM, Council of Europe)...
2024: Pharmeuropa Bio & Scientific Notes
https://read.qxmd.com/read/38519837/novel-drugs-approved-by-the-ema-the-fda-and-the-mhra-in-2023-a-year-in-review
#9
REVIEW
Andreas Papapetropoulos, Stavros Topouzis, Steve P H Alexander, Miriam Cortese-Krott, Dave A Kendall, Kirill A Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A Panettieri, Hemal H Patel, Rainer Schulz, Barbara Stefanska, Gary J Stephens, Mauro M Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy
In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer. Thirty drugs are categorized as "first-in-class" (FIC), illustrating the quality of research and innovation that drives new chemical entity discovery and development. We succinctly describe the mechanism of action of most of these FIC drugs and discuss the therapeutic areas covered, as well as the chemical category to which these drugs belong...
March 22, 2024: British Journal of Pharmacology
https://read.qxmd.com/read/38508673/drug-company-and-former-director-are-convicted-of-submitting-falsified-data-to-mhra
#10
JOURNAL ARTICLE
Elisabeth Mahase
No abstract text is available yet for this article.
March 20, 2024: BMJ: British Medical Journal
https://read.qxmd.com/read/38445365/the-novel-rapid-formulation-of-intravenous-dantrolene-npj5008-versus-standard-dantrolene-dantrium-iv-a-clinical-part-randomised-phase-1-study-in-healthy-volunteers
#11
JOURNAL ARTICLE
Richard H Ng Kwet Shing, Lucy B Clayton, Samuel L Smith, Marc J Watson, Litza M McKenzie, David P Chalmers, Gareth Whitaker, Jonathan G Bilmen
BACKGROUND: Delays in treating anaesthesia-induced malignant hyperthermia increase risks of complications and death. NPJ5008 is a novel formulation of the indicated treatment, dantrolene sodium, developed to shorten preparation and administration times compared with the reference formulation DANTRIUM IV. The two formulations have been compared preclinically. OBJECTIVES: Assess bioequivalence of overall dantrolene (free acid) exposure of NPJ5008 versus DANTRIUM IV and ascertain similarities in their pharmacokinetics and safety/tolerability profiles...
February 29, 2024: European Journal of Anaesthesiology
https://read.qxmd.com/read/38425279/editorial-first-regulatory-approvals-for-crispr-cas9-therapeutic-gene-editing-for-sickle-cell-disease-and-transfusion-dependent-%C3%AE-thalassemia
#12
EDITORIAL
Dinah V Parums
In 2020, Emmanuelle Charpentier and Jennifer Doudna were awarded the Nobel Prize in Chemistry for their research on the endonuclease, clustered regularly interspaced short palindromic repeats (CRISPR) and the CRISPR-associated protein 9 (CRISPR-Cas9) method for DNA editing. On 16 November 2023, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) was the first to approve the CRISPR-Cas9 gene editing therapy, Casgevy (exagamglogene autotemcel), for the treatment of patients with transfusion-dependent b-thalassemia and the treatment of sickle cell disease in patients aged ≥12 years with recurrent vaso-occlusive crises...
March 1, 2024: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://read.qxmd.com/read/38355982/the-impact-of-preoperative-parameters-on-postoperative-foveal-displacement-in-idiopathic-macular-hole
#13
JOURNAL ARTICLE
Hecong Qin, Jinsong Zhao, Siyan Jin, Hui Zhang
This study examined the effect of vitrectomy combined with internal limiting membrane (ILM) peeling on foveal displacement in 42 eyes with idiopathic macular hole (IMH). A retrospective analysis was conducted to measure various macular hole parameters before surgery, including basal diameter, minimum diameter, hole height, and areas affected by traction such as macular hole area (MHA), macular hole cystoid space area (MHCSA), macular hole retinal area (MHRA), and total area (TA). The results showed a postoperative shift of the fovea towards the optic disc in all cases...
February 14, 2024: Scientific Reports
https://read.qxmd.com/read/38336761/good-statistical-practice-development-of-tailored-good-clinical-practice-training-for-statisticians
#14
JOURNAL ARTICLE
Deborah D Stocken, Helen Mossop, Emma Armstrong, Steff Lewis, Susan J Dutton, Claire Peckitt, Carrol Gamble, Julia Brown
BACKGROUND: Statisticians are fundamental in ensuring clinical research, including clinical trials, are conducted with quality, transparency, reproducibility and integrity. Good Clinical Practice (GCP) is an international quality standard for the conduct of clinical trials research. Statisticians are required to undertake training on GCP but existing training is generic and, crucially, does not cover statistical activities. This results in statisticians undertaking training mostly unrelated to their role and variation in awareness and implementation of relevant regulatory requirements with regards to statistical conduct...
February 10, 2024: Trials
https://read.qxmd.com/read/38328743/assessing-the-mitochondrial-safety-profile-of-the-molnupiravir-active-metabolite-%C3%AE-d-n4-hydroxycytidine-nhc-in-the-physiologically-relevant-heparg-model
#15
JOURNAL ARTICLE
Robyn T Kiy, Saye H Khoo, Amy E Chadwick
BACKGROUND: β-d-N4-Hydroxycytidine (NHC) is the active metabolite of molnupiravir, a broad-spectrum antiviral approved by the MHRA for COVID-19 treatment. NHC induces lethal mutagenesis of the SARS-CoV-2 virus, undergoing incorporation into the viral genome and arresting viral replication. It has previously been reported that several nucleoside analogues elicit off-target inhibition of mitochondrial DNA (mtDNA) or RNA replication. Although NHC does not exert these effects in HepG2 cells, HepaRG are proven to be advantageous over HepG2 for modelling nucleoside analogue-induced mitochondrial dysfunction...
February 2024: Toxicology Research
https://read.qxmd.com/read/38292942/identifying-new-safety-risk-of-human-serum-albumin-a-retrospective-study-of-real-world-data
#16
JOURNAL ARTICLE
Hui Lu, Yuwei Zhang, Pengcheng Liu
Objective: To mine and analyze the adverse reaction signals of human serum albumin (HSA) using the FDA adverse event reporting system (FAERS) database for the safe clinical use of this drug. Methods: Data cleaning and analysis of adverse event reports in the FAERS database for a total of 76 quarters from Q1 2004 to Q4 2022 were performed using the reporting odds ratio (ROR), Medicines and Healthcare Products Regulatory Agency (MHRA), and Bayesian confidence propagation neural network (BCPNN). Gender-differentiated signal detection was used to investigate the gender differences in the occurrence of HSA adverse events...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38278703/real-world-data-and-evidence-to-support-a-switch-in-status-from-prescription-drug-to-over-the-counter-drug-as-applied-by-the-ema-the-us-fda-the-mhra-and-the-bfarm
#17
JOURNAL ARTICLE
Thomas C Kühler, Aritz Ateka, Zeineb Lassoued, François-Xavier Routhier, Souha Mékary-Sawaya
PURPOSE: We studied under which circumstances and to what extent Real-World Data (RWD) and Real-World Evidence (RWE) were used in regulatory decisions when switching products from Prescription-only (Rx) to Over-the-Counter (OTC) status with the aim of extracting learnings that could be applied in future switches. METHODS: Sanofi commissioned Clarivate Analytics to identify switches from Rx to OTC in the European Union (centrally by the European Medicines Agency [EMA] and in Germany by the Bundesinstitut für Arzneimittel und Medizinprodukte [BfArM]), in the United States by the Food and Drug Administration (FDA), and in the United Kingdom by the Medicines and Healthcare products Regulatory Agency (MHRA) as far back as data were available in the public domain, mainly Health Authority webpages...
January 25, 2024: Clinical Therapeutics
https://read.qxmd.com/read/38221762/gene-therapy-for-neurotransmitter-related-disorders
#18
REVIEW
Wing Sum Chu, Joanne Ng, Simon N Waddington, Manju A Kurian
Inborn errors of neurotransmitter (NT) metabolism are a group of rare, heterogenous diseases with predominant neurological features, such as movement disorders, autonomic dysfunction, and developmental delay. Clinical overlap with other disorders has led to delayed diagnosis and treatment, and some conditions are refractory to oral pharmacotherapies. Gene therapies have been developed and translated to clinics for paediatric inborn errors of metabolism, with 38 interventional clinical trials ongoing to date...
January 2024: Journal of Inherited Metabolic Disease
https://read.qxmd.com/read/38176347/tibial-polyethylene-post-fractures-at-ten-years-in-a-bicruciate-stabilised-bcs-total-knee-arthroplasty-design
#19
Kai Nie, Dominie Guest, John S Davidson, Alasdair J A Santini
INTRODUCTION: This short paper reports a potential emerging mode of failure in three patients with a bicruciate stabilised (BCS) total knee arthroplasty. METHODS: Three patients presented to our institution with late instability ten years after undergoing total knee arthroplasty (Journey BCS) and were asymptomatic up to this point. Retrieval analysis was performed by an external body commissioned by the NHS and all three cases were reported to the UK Medicines and Healthcare Products Regulatory Agency (MHRA)...
January 3, 2024: Knee
https://read.qxmd.com/read/38123946/mhra-issues-two-updates-on-fluoroquinolone-safety
#20
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
December 11, 2023: Drug and Therapeutics Bulletin
keyword
keyword
11771
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.